GlassScriptPhysician profile
Muhammad I Ismail
NPI 1275584211
$6,560.33
in general payments reported to CMS, 2019-2025
31 companies · $2,579 in 2025
The $2,579 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $57.17 · 2021: $177 · 2022: $428 · 2023: $1,366 · 2024: $1,954 · 2025: $2,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,898.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,898.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.28 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $850.02 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $806.79 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Almatica Pharma LLC | $475.59 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Teva Pharmaceuticals USA, INC. | $472.96 | 2020-2025 | Austedo Xr, Austedo Xr, Austedo |
| Vanda Pharmaceuticals INC. | $423.31 | 2023-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $416.68 | 2023-2025 | Rexulti |
| Eisai INC. | $267.75 | 2021-2025 | |
| Alkermes, INC. | $247.31 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Neurocrine Biosciences, INC. | $214.52 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $193.20 | 2024-2025 | Auvelity |
| Pfizer INC. | $171.75 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $141.85 | 2024-2025 | Spravato |
| Aucta Pharmaceuticals, INC. | $129.35 | 2024-2025 | Motpoly Xr |
| Indivior INC. | $122.55 | 2022-2024 | Perseris |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $120.45 | 2022-2025 | Kisunla, Amyvid |
| Mdd US Operations, LLC | $84.15 | 2022-2023 | Apokyn |
| Ucb, INC. | $69.67 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.02 | 2022 | |
| Amneal Pharmaceuticals LLC | $43.69 | 2024 | Ongentys, Rytary |
| Noven Therapeutics, LLC | $43.64 | 2024 | Secuado, Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $39.17 | 2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $37.94 | 2025 | Qelbree |
| Corium, LLC | $36.43 | 2022-2023 | Adlarity |
| C2n Diagnostics, LLC | $35.49 | 2025 | Precivityad2 |
| Tms Neurohealth Centers INC. | $28.75 | 2025 | Tms Neurohealth Centers INC. |
| Hyperfine Operations, INC. | $26.49 | 2025 | Swoop |
| Catalyst Pharmaceuticals, INC. | $23.39 | 2024 | |
| Merck Sharp & Dohme LLC | $17.72 | 2022 | |
| Biogen, INC. | $17.58 | 2022 | |
| Allergan, INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.